Thu, Mar 27, 11:31 AM (31 days ago)
### Summary of Savara Inc. (SVRA) 10-K **Financial Performance:** - **Revenue:** $0 (no product revenue) - **Net Loss:** $95.9 million (2024), $54.7 million (2023) - **Operating Expenses:** $103.2 million (2024), $60.0 million (2023) - **Cash Flow:** $89.1 million used in operating activities (2024), $51.1 million (2023) **Earnings per Share:** - **Basic and Diluted Net Loss per Share:** $0.48 (2024), $0.33 (2023) **Financial Condition:** - **Cash and Cash Equivalents:** $15.1 million (2024) - **Short-Term Investments:** $181.2 million (2024) - **Accumulated Deficit:** $489.3 million (2024) - **Debt:** $26.6 million (2024) **Strategic Overview:** - **Product Candidate:** MOLBREEVI (molgramostim inhalation solution) for autoimmune pulmonary alveolar proteinosis (aPAP) - **Clinical Trials:** Positive top-line results from Phase 3 IMPALA-2 trial; BLA submission completed - **Regulatory Status:** Fast Track and Breakthrough Therapy Designations; Orphan Drug Designation **Future Outlook:** - **Funding:** $196.3 million in cash, cash equivalents, and short-term investments (2024); potential additional financing through equity offerings, debt, or strategic alliances - **Operational Focus:** Continued development of MOLBREEVI, regulatory approval, and potential commercialization **Risk Factors:** - **Clinical Development:** Uncertainty in clinical trial outcomes, regulatory approval, and market acceptance - **Financial:** Dependence on additional financing, potential delays in product development, and market risks - **Operational:** Dependence on third-party manufacturers, supply chain risks, and potential disruptions due to geopolitical events **Market Position Changes:** - **Competitive Landscape:** Potential competition from other treatments and off-label use of similar products - **Market Potential:** Significant unmet need for aPAP treatment; potential market exclusivity through Orphan Drug Designation **Note:** Amounts are usually in thousands, 000s.